Care Bundle Approach to Reduce Surgical Site Infections in Acute Surgical Intensive Care Unit, Cairo, Egypt
Overview
Affiliations
Introduction: Surgical site infections (SSIs) are one of the most frequently reported hospital acquired infections associated with significant spread of antibiotic resistance.
Purpose: We aimed to evaluate a bundle-based approach in reducing SSI at acute surgical intensive care unit of the Emergency Hospital of Cairo University.
Patients And Methods: Our prospective study ran from March 2018 to February 2019 and used risk assessment. The study was divided into three phases. Phase I: (pre-bundle phase) for 5 months; data collection, active surveillance of the SSIs, screening for OXA-48 producing and multidrug resistant colonizers using Chrom agars were carried out. Phase II: (bundle-implementation) a 6-S bundle approach included education, training and postoperative bathing with Chlorhexidine Gluconate in collaboration with the infection control team. Finally, Phase III: (post-implementation) for estimation of compliance, rates of colonization, and infection.
Results: Phase I encompassed 177 patients, while Phase III included 93 patients. A significant reduction of colonization from 24% to 15% (p<0.001) was observed. Similarly, a decrease of SSI from 27% to 15% (p=0.02) was noticed. A logistic regression was performed to adjust for confounding in the implementation of the bundle and we found a 70% reduction of SSI odd's ratio (OR's ratio = 0.3) confidence interval (95% CI 0.14-0.6) with significant Apache II (p=0.04), type of wound; type II (p=0.002), type III (p=0.001) and duration of surgery (p=0.04) as independent risk factors for SSI. was the most prevalent organism during phase I (34.7%). On the other hand, was the commonest organism to be isolated during phase III with (38.5%) preceding (30%).
Conclusion: Our study demonstrated that the implementation of a multidisciplinary bundle containing evidence-based interventions was associated with a significant reduction of colonization and SSIs and was met with staff approval and acceptable compliance.
Zhu W, Liang Y, Xu J, Weng C Infect Drug Resist. 2025; 18:757-768.
PMID: 39931038 PMC: 11809232. DOI: 10.2147/IDR.S506658.
Brainard J, Swindells I, Wild J, Hammer C, Hornsey E, Mahamed H BMC Health Serv Res. 2024; 24(1):937.
PMID: 39152446 PMC: 11328436. DOI: 10.1186/s12913-024-11408-y.
Wassef M, Ghaith D, Hussien M, El-Shazly M, Yousef R BMC Infect Dis. 2024; 24(1):674.
PMID: 38969966 PMC: 11225324. DOI: 10.1186/s12879-024-09525-4.
Elwakil W, Rizk S, El-Halawany A, Rateb M, Attia A Antibiotics (Basel). 2023; 12(1).
PMID: 36671278 PMC: 9854726. DOI: 10.3390/antibiotics12010077.